Reach The ProFACT Value Proposition in Personalized Medicine
In the 'omics' universe today, each discipline independently prospects for biomarkers, but for reasons both technical and commercial, there is little crosstalk between the disciplines. Most importantly, the current 'omics' paradigm inefficiently delivers biomarkers productive to Biopharma. Massive infrastructures support sequence annotation, dominating the industry with the hope that cellular function can some day be inferred from sequence only. Yet, while proteomic advancements continue to better annotate sequence, functional annotation is necessary to advance compounds to the clinic. Such functional annotation lags far behind sequence annotation. New and better functional annotations for Proteomics is necessary to coincide with biopharma's core excellence in small molecule compound development. Here's why:
From the perspective of Biopharma, the 'omics' universe looks like the planet of the lost compounds. By this we mean, the thousands of compounds in the vault that are under-valued, under-utilized or otherwise cannot be commercialized. These include compounds that exhibit a cellular response (cytotoxicity to cancer cells for example), or compounds with known inhibition towards certain classes of enzymes (kinases for example), but with no suitable disease phenotype to modulate for therapeutic effect.
But sequence annotation - the deliverable of conventional proteomics, is not particularly constituted to discover indications and to identify protein responsive markers for such compounds. This is because drugs work by modulating protein function. Many successful drugs are promiscuous, modulating multiple proteins at once, while toxicity can often come from modulation of off-targets. So understanding mechanism of action and indications discovery requires functional annotation. What the 'omics' industry largely disregards is the gorilla in the room for personalized medicine, which is that the same underlying sequence can have multiple conformations and functions, and different sequences sometimes perform the same or similar functions. Drug promiscuity compounds these problems. So new functional proteomic strategies are necessary.
ProFACT's proprietary platform, SeraFILE and its associated prospecting methods, fulfills this purpose delivering functional proteomic information that can complement and integrate with sequence annotation. By adapting our advances in separations technology to data-reporting infrastructure already available, functional proteomic characterizations can be more precisely resolved and annotated.
To better understand SeraFILE™ or its three application areas, click on the links below:
SeraFILE™
Functional Proteome Prospecting™
Conformerics™
Rational Genome to Proteome Prospecting™
Partnerships and Services
We work collaboratively with our clients to customize applications to their research projects. Protocols developed are transferable to the client if desired. ProFACT maintains a high-throughput functional proteomics laboratory and network of 3rd parties for ancillary data requirements.
ProFACT works with clients on both a partnership and fee-for-service basis. Partnerships typically take the form of a negotiated contribution from both parties, with both participating in the results and discoveries. Fee-for-service relationships are client sponsored research whereby the client enjoys unimpeded, complete and exclusive rights, subject to no further compensation, to exploit all information and discoveries that arise from such research.
Confidentiality: ProFACT will not disclose any information obtained in the course of the services provided to clients without the express consent of the client. Confidentiality Agreements are often executed.
Talk to us about your drug development or system biology requirements. For more information, contact Matthew Kuruc at 732-230-3021 or mkuruc@profactproteomics.com.
